Trial Profile
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 31 Mar 2017 Status changed from completed to discontinued.
- 21 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 12 Mar 2015 New trial record